




RealRate

PHARMACEUTICAL 2017

Actinium Pharmaceuticals Inc. Rank 172 of 292





RealRate

PHARMACEUTICAL 2017

Actinium Pharmaceuticals Inc. Rank 172 of 292



The relative strengths and weaknesses of Actinium Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Actinium Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 68% points. The greatest weakness of Actinium Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 79% points.

The company's Economic Capital Ratio, given in the ranking table, is 49%, being 46% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	22,390
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,521
Liabilities, Non-Current	0
Other Assets	50
Other Compr. Net Income	0
Other Expenses	78
Other Liabilities	0
Other Net Income	2,526
Other Revenues	0
Property and Equipment	89
Research and Development	17,501
Selling, General and Administrative Expense	9,269

Output Variable	Value in 1000 USD
Assets	22,529
Liabilities	4,521
Expenses	26,847
Revenues	0
Stockholders Equity	18,008
Net Income	-24,322
Comprehensive Net Income	-24,322
Economic Capital Ratio	49%